Levothyroxine dose and risk of fractures in older adults: Nested case-control study

BMJ

Volumn 342, Issue 7805, 2011, Pages

  Turner, Marci R ^a   Camacho, Ximena ^b   Fischer, Hadas D ^b   Austin, Peter C ^b   Anderson, Geoff M ^c   Rochon, Paula A ^d   Lipscombe, Lorraine L ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; NEUROLEPTIC AGENT; OPIATE; PROTON PUMP INHIBITOR; SEDATIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; THYROXINE;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; FEMALE; FOREARM FRACTURE; FRACTURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHOULDER FRACTURE; SPINE FRACTURE; THORACIC SPINE; WRIST FRACTURE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; FOLLOW UP; HYPOTHYROIDISM; MALE; RISK FACTOR;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; HYPOTHYROIDISM; MALE; RISK FACTORS; THYROXINE;

EID: 79955668280     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d2238     Document Type: Article

References (70)

1. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803.
2. Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2002 to 2008. CIHI, 2010.
3. Mooradian AD. Normal age-related changes in thyroid hormone economy. Clin Geriatr Med 1995;11:159-69.
4. Robbins J. Factors altering thyroid hormone metabolism. Environ Health Perspect 1981;38:65-70. (Pubitemid 11036371)
5. Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P. The aging thyroid. The use of thyroid hormone in older persons. JAMA 1989;261:2653-5.
6. Hall R, Scanlon MF. Hypothyroidism: clinical features and complications. Clin Endocrinol Metab 1979;8:29-38. (Pubitemid 9126097)
7. Use of Thyroid Function Tests Guidelines Development Group. UK guidelines for the use of thyroid function tests. British Thyroid Foundation, 2006.
8. Guidelines and Protocols Advisory Committee. Thyroid function tests: diagnoses and monitoring of thyroid function disorders in adults. Medical Services Commission, 2010.
9. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502. (Pubitemid 23310112)
10. De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. Br J Gen Pract 1995;45:93-5.
11. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-34. (Pubitemid 30112276)
12. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;113:265-9. (Pubitemid 20254352)
13. Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, Chen Z, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010;170:1876-83.
14. Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone overreplacement and under-replacement in men and women aged 65 and over. J Clin EndocrinolMetab 2009;94:1342-5.
15. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl JMed 1995;332:767-73.
16. Leslie WD, Anderson WA, Metge CJ, Manness LJ: Maximizing Osteoporosis Management in Manitoba Steering Committee. Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study. Bone 2007;40:991-6.
17. Bauer DC, Ettinger B, Nevitt MC, Stone KL: Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561-8.
18. Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 2004;15:209-16. (Pubitemid 38391536)
19. Hadji P, Hars O, Sturm G, Bauer T, Emons G, Schulz KD. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 2000;142:445-50. (Pubitemid 30341174)
20. Duncan WE, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid 1994;4:183-90. (Pubitemid 24202353)
21. Grant DJ, McMurdo ME, Mole PA, Paterson CR, Davies RR. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol (Oxf) 1993;39:529-33. (Pubitemid 23323949)
22. Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA, Meunier PJ. Hyperthyroidism influences ultrasound bone measurement on the os calcis. Osteoporos Int 1998;8:455-9. (Pubitemid 28486714)
23. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 2006;16:375-80.
24. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl JMed 1994;331:1249-52. (Pubitemid 24333188)
25. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142:838-42. (Pubitemid 33016203)
26. Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G. Hip fractures and the thyroid: a case-control study. J Intern Med 1995;237:241-7.
27. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 2002;162:338-43. (Pubitemid 34127412)
28. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-93.
29. Vestergaard P, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Rejnmark L, et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 2000;10:335-40. (Pubitemid 30256863)
30. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 2005;77:139-44. (Pubitemid 41569743)
31. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl JMed 1986;314:1676-86. (Pubitemid 16097845)
32. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99.
33. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007;297:387-94. (Pubitemid 46155800)
34. Hoogendoorn EH, den Heijer M, van Dijk AP, Hermus AR. Subclinical hyperthyroidism: to treat or not to treat? Postgrad Med J 2004;80:394-8.
35. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-38. (Pubitemid 38082818)
36. Ross DS, Ardisson LJ, Meskell MJ. Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. J Clin Endocrinol Metab 1989;69:684-8. (Pubitemid 19221247)
37. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71. (Pubitemid 37028596)
38. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002;144:290-6. (Pubitemid 34879653)
39. Joseph KS, Fahey J: Canadian Perinatal Surveillance System. Validation of perinatal data in theDischarge Abstract Database of the Canadian Institute for Health Information. Chronic Dis Can 2009;29:96-100.
40. Hawker GA, Coyte PC, Wright JG, Paul JE, Bombardier C. Accuracy of administrative data for assessing outcomes after knee replacement surgery. J Clin Epidemiol 1997;50:265-73. (Pubitemid 27165703)
41. Richards J, Brown A, Homan C. The data quality study of the Canadian discharge abstract database. Achieving data quality in a statistical agency: a methodological perspective. Proceedings of Statistics Canada Symposium. Statistics Canada, 2001.
42. Leslie WD, O'Donnell S, Jean S, Lagace C, Walsh P, Bancej C, et al. Trends in hip fracture rates in Canada. JAMA 2009;302:883-9.
43. Mamdani M, Kopp A, Hawker G. Hip fractures in users of first- vs second-generation bisphosphonates. Osteoporos Int 2007;18:1595-600. (Pubitemid 47620321)
44. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, et al. Fracture types and risk factors inmenwith prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010;184:918-23.
45. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6. (Pubitemid 41103345)
46. Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol 2006;59:67-76. (Pubitemid 41797477)
47. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. (Pubitemid 36143396)
48. Trimpou P, Landin-Wilhelmsen K, Oden A, Rosengren A, Wilhelmsen L. Male risk factors for hip fracture-a 30-year follow-up study in 7,495 men. Osteoporos Int 2009;21:409-16.
49. Weller I, Schatzker J. Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol 2004;14:319-24. (Pubitemid 38737324)
50. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treatedwith amiodarone or digoxin for cardiac arrhythmias: a nationwide case-control study. Osteoporos Int 2007;18:409-17. (Pubitemid 46354913)
51. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82. (Pubitemid 38953182)
52. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39. (Pubitemid 30174026)
53. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-7. (Pubitemid 28195906)
54. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007;167:188-94. (Pubitemid 46148067)
55. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32.
56. Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 1982;70:716-23. (Pubitemid 12038087)
57. Dennis MS, Lo KM, McDowall M, West T. Fractures after stroke: frequency, types, and associations. Stroke 2002;33:728-34. (Pubitemid 34203999)
58. Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, et al. Risk of hip/femur fracture after stroke: a populationbased case-control study. Stroke 2009;40:3281-5.
59. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bonemineral density in elderlywomen. Effects of estrogen. JAMA 1994;271:1245-9.
60. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1985;6:421-8. (Pubitemid 16184793)
61. Okosieme OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of thyroid hormone replacement in a general population. QJM 2010; published online 24 November.
62. Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983;75:206-9. (Pubitemid 13030858)
63. Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 2010;46:747-51.
64. Surks MI, Boucai L. Age- and race-based serumthyrotropin reference limits. J Clin Endocrinol Metab 2010;95:496-502.
65. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005;16:1330-8. (Pubitemid 41532085)
66. Kopec JA, Esdaile JM. Bias in case-control studies. A review. J Epidemiol Community Health 1990;44:179-86. (Pubitemid 20327418)
67. Ernster VL. Nested case-control studies. Prev Med 1994;23:587-90. (Pubitemid 24377866)
68. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-90. (Pubitemid 37281701)
69. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
70. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Wiley, 2005:811-29.